Antiplatelet Therapy is Associated with Decreased Transfusion-associated Risk of Lung Dysfunction, Multiple Organ Failure, and Mortality in Trauma Patients
Overview
Emergency Medicine
Authors
Affiliations
Objective: To determine whether prehospital antiplatelet therapy was associated with reduced incidence of acute lung dysfunction, multiple organ failure, and mortality in blunt trauma patients.
Design: Secondary analysis of a cohort enrolled in the National Institute of General Medical Sciences Trauma Glue Grant database.
Setting: Multicenter study including nine U.S. level-1 trauma centers.
Patients: A total of 839 severely injured blunt trauma patients at risk for multiple organ failure (age > 45 yr, base deficit > 6 mEq/L or systolic blood pressure < 90 mm Hg, who received a blood transfusion). Severe/isolated head injuries were excluded.
Measurements And Main Results: Primary outcomes were lung dysfunction (defined as grades 2-3 by the Denver multiple organ failure score), multiple organ failure (Denver multiple organ failure score >3), and mortality. Patients were documented as on antiplatelet therapy if taking acetylsalicylic acid, clopidogrel, and/or ticlopidine. Fifteen percent were taking antiplatelet therapy prior to injury. Median injury severity score was 30 (interquartile range 22-51), mean age 61 + 0.4 yr and median RBCs volume transfused was 1700 mL (interquartile range 800-3150 mL). Overall, 63% developed lung dysfunction, 19% had multiple organ failure, and 21% died. After adjustment for age, gender, comorbidities, blood products, crystalloid/12 hrs, presence of any head injury, injury severity score, and 12 hrs base deficit > 8 mEq/L, 12 hrs RBC transfusion was associated with a significantly smaller risk of lung dysfunction and multiple organ failure among the group receiving antiplatelet therapy compared with those not receiving it (lung dysfunction p = 0.0116, multiple organ failure p = 0.0291). In addition, antiplatelet therapy had a smaller risk (albeit not significant, p = 0.06) of death for patients receiving RBC compared to those not on antiplatelet therapy after adjustment for confounders,
Conclusions: Pre-injury antiplatelet therapy is associated with a decreased risk of lung dysfunction, multiple organ failure, and possibly mortality in high-risk blunt trauma patients who received blood transfusions. These findings suggest platelets have a role in organ dysfunction development and have potential therapeutic implications.
Meng Y, Lin Y, Zhang J, Zou W, Liu Y, Shen X Front Pharmacol. 2023; 14:1292745.
PMID: 38034989 PMC: 10682711. DOI: 10.3389/fphar.2023.1292745.
Yamaji F, Okada H, Kamidani R, Kawasaki Y, Yoshimura G, Mizuno Y Front Med (Lausanne). 2023; 9:1089219.
PMID: 36698798 PMC: 9868405. DOI: 10.3389/fmed.2022.1089219.
Greve F, Aulbach I, Mair O, Biberthaler P, Hanschen M Medicina (Kaunas). 2022; 58(7).
PMID: 35888620 PMC: 9317692. DOI: 10.3390/medicina58070901.
Platelet dysfunction after trauma: From mechanisms to targeted treatment.
Sloos P, Vulliamy P, Veer C, Sen Gupta A, Neal M, Brohi K Transfusion. 2022; 62 Suppl 1:S281-S300.
PMID: 35748694 PMC: 9546174. DOI: 10.1111/trf.16971.
Greve F, Mair O, Aulbach I, Biberthaler P, Hanschen M J Clin Med. 2022; 11(5).
PMID: 35268491 PMC: 8911048. DOI: 10.3390/jcm11051400.